analyst coverage | GenomeWeb

analyst coverage

The investment bank set a price target of $18.00 for shares of the molecular diagnostics company. 

The investment bank provided the updates as part of its 2017 outlook on the US life science tools and diagnostics markets.

Evercore said that Hologic's recent divestiture of its blood screening business limits near-term EPS growth; Piper, however, is looking forward to 2018.

The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.

The investment bank also changed ratings for several omics companies, and revised price targets and estimates throughout its portfolio.

The investment bank noted Veracyte's "disciplined" approach to developing and commercializing tests, and said the company stands out in its sector.

The investment bank said Veracyte's negative classifier tests are of significant value to healthcare providers and payors.

The investment bank said Danaher's recent acquisitions of Cepheid and Phenomenex increase its potential for revenue growth.

In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.

The investment bank, which also set a 12-month price target of $5 for the company's shares, said it anticipates a growing footprint for the HTG EdgeSeq system.

Pages

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.